Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 18/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 18/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26136027 | 0.98 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP3A4CALM1 | |
| SCHEMBL21251416 | 0.86 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL28544958 | 0.85 | CALM1 (0.60) | CYP11B1CYP11B2CYP3A4CALM1 | |
| SCHEMBL19540958 | 0.84 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL26466869 | 0.81 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL12659904 | 0.79 | TSHR (0.54) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL5364704 | 0.79 | SRD5A2 (0.58) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL2716882 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL20826965 | 0.77 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL25122223 | 0.77 | CYP11B1 (0.49) | CYP11B1CYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | CYP11B1 307/4885CYP11B2 483/4885CYP3A4 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.